Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)

Inclusion Criteria: * Participant has an histopathologically confirmed follicular lymphoma (FL), or other indolent B-cell non-Hodgkin's lymphoma (B-NHL) or mantle cell lymphoma (MCL) * Only relapsed/refractory FL can be included outside Japan * Participant has at least one measurable lesion by computerized tomography (CT) scan which is defined by Cheson's 1999 criteria * Participant has received at least 1 but up to 4 prior chemotherapeutic regimens, the most recent therapy must have failed to induce a partial response, or there must be recurrence in case of the most recent therapy has shown complete response, or there must be relapse in case of the most recent therapy has shown partial response * Life expectancy of \>4 months * Participant must have adequate organ and marrow function * Women of child bearing potential must be negative for pregnancy and agree to use effective contraceptive measures until 30 days after the last dose of MK-0683. * Men must agree to use effective contraceptive measures until 6 months after the last dose of MK-0683 Exclusion Criteria: * Participant has undergone allogenic transplant treatment or autologous stem cell transplant within 6 months * Participant with other active malignancies or central neurological infiltration with lymphoma * Participant with severe hepatic insufficiency * Participant with history of allergic reactions attributed to any component of MK-0683 * Participant is known to be human immunodeficiency virus (HIV) antibod…